CoChat
Sign Up
Cited by 410Lymphoma Diagnosis and TreatmentMedical Imaging Techniques and ApplicationsHematological disorders and diagnostics

The DOI matches its Crossref record; 28 of the 30 references it cites were found in a registry or an index.

Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma

Open access
Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J., de Groot, T., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., Verhoef, G.·2002·Annals of Oncology
DOI 10.1093/annonc/mdf256
Open this paper in CoChat — free accountOpen PDF

Abstract

Background Less than half of all patients with aggressive non-Hodgkin's lymphoma (NHL) are cured with standard chemotherapy. Therefore, it is important to distinguish between responders to standard treatment and non-responders who may benefit from an early change to a more effective therapy. This study was intended to assess the value of a midtreatment fluorine-18 fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) scan to predict clinical outcome in patients with aggressive NHL.Patients and methods Seventy newly diagnosed patients with aggressive NHL, who were treated with doxorubicin-containing chemotherapy, underwent a [(18)F]FDG-PET scan at midtreatment. Presence or absence of abnormal [(18)F]FDG uptake was related to progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier survival analysis. Multivariate analysis was performed to evaluate the effect of the International Prognostic Index (IPI) and early [(18)F]FDG-PET findings on PFS and OS.Results At midtreatment, 33 patients showed persistent abnormal [(18)F]FDG uptake and none of these patients achieved a durable complete remission (CR), whereas 37 patients showed a negative scan; 31/37 remained in CR, with a median follow-up of 1107 days. Only 6/37 patients either achieved a partial response or relapsed. Comparison between groups indicated a statistically significant association between [(18)F]FDG-PET findings and PFS (P <1 x 10(-5)) and OS (P <1 x 10(-5)). In multivariate analysis, [(18)F]FDG-PET at midtreatment was a stronger prognostic factor for PFS (P <1 x 10(-7)) and OS (P <9 x 10(-6)) than the IPI (P <0.11 and P <0.03, respectively).Conclusions Early restaging [(18)F]FDG-PET may be used to tailor induction chemotherapy in patients with aggressive NHL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdf256

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 30 references

2 of the 30 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. 2000, The first international symposium on biology and treatment of aggressive lymphomas. The stagnation seems to be over, Ann Hematol 2001, 80, B1

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J., de Groot, T., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., & Verhoef, G.
Affiliations
Universitair Ziekenhuis Leuven (BE)
Corresponding author
Spaepen, K.
ORCID
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2002-09
Volume
13
Issue
9
Pages
1356-1363
ISSN
0923-7534 (ISSN-L)
DOI
10.1093/annonc/mdf256
OpenAlex
W1990827442
Cited by
410
References
30
Citations by year
2026: 2 · 2025: 1 · 2023: 3 · 2022: 11 · 2021: 7 · 2020: 6 · 2019: 4 · 2018: 2 · 2017: 15 · 2016: 18 · 2015: 17 · 2014: 14 · 2013: 25 · 2012: 25
FWCI
12.74
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Fonds Wetenschappelijk Onderzoek
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Health Sciences › Medicine › Hematology › Hematological disorders and diagnostics
Keywords
aggressive non-Hodgkin lymphoma, 18F-FDG PET, treatment response prediction, progression-free survival, overall survival, International Prognostic Index, complete remission, prognostic factors, treatment response monitoring
MeSH terms
Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Cyclophosphamide, Doxorubicin, Evaluation Studies as Topic, Female, Humans, Lymphoma, Non-Hodgkin, Male, Middle Aged, Monitoring, Physiologic, Neoplasm Staging, Predictive Value of Tests, Prednisolone, Probability, Prognosis, Prospective Studies, Sensitivity and Specificity, Time Factors, Tomography, Emission-Computed, Vincristine, Survival Rate, Multivariate Analysis, Treatment Outcome, Fluorodeoxyglucose F18

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review